Imbria Pharmaceuticals is a clinical stage biotechnology company developing novel therapies for patients with life-altering cardiometabolic disorders. The company focuses on restoring or improving the cell's ability to produce energy in cardiometabolic disorders where energetic impairment is a fundamental contributor to disease pathogenesis, symptoms, and functional deficits.
Market
Cardiometabolic diseases
Location
Boston,
MA,
USA
Coinvestors
Deep Track Capital, AN Ventures, Catalio Capital Management, Cytokinetics, Inc., RA Capital Management, SV Health Investors